Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Significant Drop in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 165,200 shares, a drop of 22.7% from the March 31st total of 213,800 shares. Based on an average trading volume of 81,400 shares, the short-interest ratio is presently 2.0 days. Currently, 0.6% of the company’s stock are sold short.

Senti Biosciences Trading Up 16.2 %

SNTI stock traded up $0.05 during mid-day trading on Tuesday, hitting $0.36. 2,388,760 shares of the company were exchanged, compared to its average volume of 132,253. The company has a market capitalization of $16.47 million, a PE ratio of -0.23 and a beta of 2.96. Senti Biosciences has a twelve month low of $0.27 and a twelve month high of $1.10. The firm has a fifty day simple moving average of $0.37 and a 200 day simple moving average of $0.41.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative return on equity of 74.59% and a negative net margin of 2,692.82%. As a group, sell-side analysts anticipate that Senti Biosciences will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SNTI. 8VC GP I LLC bought a new position in shares of Senti Biosciences in the 4th quarter worth about $1,675,000. ARK Investment Management LLC lifted its position in shares of Senti Biosciences by 7.9% in the 4th quarter. ARK Investment Management LLC now owns 1,969,860 shares of the company’s stock worth $1,300,000 after buying an additional 143,785 shares during the last quarter. Finally, TD Asset Management Inc lifted its position in shares of Senti Biosciences by 88.4% in the 3rd quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock worth $102,000 after buying an additional 113,172 shares during the last quarter. 25.73% of the stock is currently owned by institutional investors.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.